Larimar Therapeutics Business Summary

Larimar Therapeutics, Inc. (LRMR) is a clinical-stage biotechnology company that operates on a research-and-development business model, currently generating zero revenue as it advances its proprietary cell-penetrating peptide (CPP) technology platform. The company focuses exclusively on the rare disease segment, utilizing its platform to deliver functional proteins directly into the mitochondria of cells to treat complex genetic disorders. Its lead asset, nomlabofusp (formerly CTI-1601), is a first-in-class protein replacement therapy for Friedreich’s ataxia (FA) that recently received FDA Breakthrough Therapy Designation in February 2026. Larimar is positioned as a high-potential disease-modifying contender in a market currently led by Biogen (via the acquisition of Reata’s Skyclarys), while also competing with PTC Therapeutics and gene-therapy developers like Voyager Therapeutics. Unlike competitors focusing on Nrf2 activation or gene editing, Larimar distinguishes itself through a direct protein-restoration approach, targeting a Biologics License Application (BLA) submission in June 2026 for accelerated approval. The company was founded in 2013 as Chondrial Therapeutics by Dr. R. Mark Payne of the Indiana University School of Medicine and former Eli Lilly executive Steve Plump, later going public via a 2020 reverse merger with Zafgen. The leadership team is led by President and CEO Dr. Carole Ben-Maimon, whose pedigree includes executive roles at Teva Pharmaceutical Industries, Barr Pharmaceuticals, and Deerfield Management. Supporting her are CFO Michael Celano, formerly of Recro Pharma and OraSure Technologies, and Chief Development Officer Dr. Gopi Shankar, who previously led biologics development at Janssen (Johnson & Johnson). The board is chaired by Joseph Truitt, the former CEO of Achillion Pharmaceuticals and BioSpecifics Technologies. Larimar maintains a robust institutional pedigree with significant backing from notable life science investors including Deerfield Management, RA Capital Management, OrbiMed, and BlackRock.